Skip to main content

NEO:HALO - Halozyme Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: C$0.24
  • Forecasted Upside:
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
C$0.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Halozyme Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HALO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HALO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
C$0.24
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Halozyme Therapeutics in the last 3 months. The average price target is C$0.24, with a high forecast of C$0.24 and a low forecast of C$0.24. The average price target represents a ∞ upside from the last price of C$0.00.

Strong Buy

The current consensus among 1 contributing investment analysts is to buy (strong buy) stock in Halozyme Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/20/2021Fundamental ResearchLower Price TargetTop Pick ➝ Top PickC$0.27 ➝ C$0.24
i
3/11/2021Fundamental ResearchInitiated CoverageTop PickC$0.27
i
(Data available from 5/16/2016 forward)
Halozyme Therapeutics logo
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

1,176,334 shs

Average Volume

1,315,665 shs

Market Capitalization

N/A

P/E Ratio

47.29

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Halozyme Therapeutics?

The following sell-side analysts have issued reports on Halozyme Therapeutics in the last year: Fundamental Research.
View the latest analyst ratings for HALO.

What is the current price target for Halozyme Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Halozyme Therapeutics in the last year. Their average twelve-month price target is C$0.24. Fundamental Research has the highest price target set, predicting HALO will reach C$0.24 in the next twelve months. Fundamental Research has the lowest price target set, forecasting a price of C$0.24 for Halozyme Therapeutics in the next year.
View the latest price targets for HALO.

What is the current consensus analyst rating for Halozyme Therapeutics?

Halozyme Therapeutics currently has 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for HALO.

What other companies compete with Halozyme Therapeutics?

How do I contact Halozyme Therapeutics' investor relations team?

The company's listed phone number is 858 794 8889. The official website for Halozyme Therapeutics is www.halozyme.com.